Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year.
Atopic dermatitis patients now have a new therapeutic option that comes as a topical cream. The FDA approved Incyte’s drug, Opzelura, as a treatment for the inflammatory skin condition, but the regulatory nod comes with a black box warning on the label that broadly covers the entire class of JAK inhibitors.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
The company is developing abrocitinib, a JAK1 inhibitor, for the disease. Incyte is also developing a topical formulation of its JAK2 inhibitor for atopic dermatitis.